acute kidney injury risk with androgen deprivation therapy

Reactions 1465, p4 - 17 Aug 2013 Acute kidney injury risk with androgen deprivation therapy Use of androgen deprivation therapy (ADT) significantly increases the risk of acute kidney injury (AKI) in patients with prostate cancer, according to researchers from the UK. The researchers conducted a nested case-control analysis using data from the UK Clinical Practice Research Datalink and Hospital Episodes Statistics database. Men aged ≥ 40 years with newly diagnosed nonmetastatic prostate cancer between January 1997 and December 2009 were identified and followed-up until December 2009. Exposure to ADT was assessed from prescription information. Cases (patients hospitalised for the first time for AKI; n = 232) were matched with controls (n = 2721) by age, calendar year of cohort entry and duration of follow-up. Current, but not past, use of ADT was associated with a significantly increased risk of AKI compared with never use (odds ratio [OR] 2.48; 95% CI 1.61, 3.82), with a difference in the AKI rate of 4.43/1000 persons per year. With respect to ADT types, AKI risk was significantly increased with the use of combined androgen blockade (OR 4.50), estrogens (4.0), other combination therapies (4.04) and gonadotropin-releasing hormone agonists (1.93). "These findings require replication in other well- designed studies as well as further investigation of their clinical importance," note the researchers. Lapi F, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA: the Journal of the American Medical Association 310: 289-96, No. 3, 17 Jul 2013. Available from: URL: http:// dx.doi.org/10.1001/jama.2013.8638 803091327 1 Reactions 17 Aug 2013 No. 1465 0114-9954/13/1465-0001/$14.95 Adis © 2013 Springer International Publishing AG. All rights reserved

Upload: doandiep

Post on 20-Jan-2017

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

Reactions 1465, p4 - 17 Aug 2013

Acute kidney injury risk withandrogen deprivation therapy

Use of androgen deprivation therapy (ADT)significantly increases the risk of acute kidney injury(AKI) in patients with prostate cancer, according toresearchers from the UK.

The researchers conducted a nested case-controlanalysis using data from the UK Clinical PracticeResearch Datalink and Hospital Episodes Statisticsdatabase. Men aged ≥ 40 years with newly diagnosednonmetastatic prostate cancer between January 1997and December 2009 were identified and followed-upuntil December 2009. Exposure to ADT was assessedfrom prescription information. Cases (patientshospitalised for the first time for AKI; n = 232) werematched with controls (n = 2721) by age, calendar yearof cohort entry and duration of follow-up.

Current, but not past, use of ADT was associated witha significantly increased risk of AKI compared with neveruse (odds ratio [OR] 2.48; 95% CI 1.61, 3.82), with adifference in the AKI rate of 4.43/1000 persons per year.With respect to ADT types, AKI risk was significantlyincreased with the use of combined androgen blockade(OR 4.50), estrogens (4.0), other combination therapies(4.04) and gonadotropin-releasing hormone agonists(1.93). "These findings require replication in other well-designed studies as well as further investigation of theirclinical importance," note the researchers.Lapi F, et al. Androgen deprivation therapy and risk of acute kidney injury inpatients with prostate cancer. JAMA: the Journal of the American MedicalAssociation 310: 289-96, No. 3, 17 Jul 2013. Available from: URL: http://dx.doi.org/10.1001/jama.2013.8638 803091327

ANovelSalicylanilideDerivativeInducesAutophagyCell Death ... · metastatic CRPC. Introduction Despite high response rates to androgen deprivation therapy in men with advanced prostate

2014 FRAX Based Lebanese Osteoporosis Guidelines · Chronic glucocorticoid therapy (>3-6 months) Aromatase inhibitors or androgen deprivation therapy All other indications in postmenopausal

Androgen Deprivation Therapy Educational Program...• Receive a free copy of the book: Androgen Deprivation Therapy: An Essential Guide for Prostate Cancer Patients and Their Loved

Zytiga, INN-abiraterone acetate · The objective of therapy is control of disease while maintaining quality of life. The initial approach is generally androgen deprivation therapy

Androgen-RegulatedandHighlyTumorigenicHumanProstate ... · Androgen-RegulatedandHighlyTumorigenicHumanProstate CancerCellLineEstablishedfromaTransplantablePrimary CWR22Tumor AyushDagvadorj,

Scoping Document Clinical Effectiveness, Safety and Cost ......Enzalutamide, Apalutamide or Radiotherapy plus Androgen Deprivation Therapy versus Androgen Deprivation Therapy Alone

Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT …€¦ · Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive

researchportal.northumbria.ac.uk€¦ · Web viewExercise-induced attenuation of treatment side-effects in newly diagnosed prostate cancer patients beginning androgen deprivation

Social deprivation, ethnicity and access to kidney transplantation in England and Wales Udaya Udayaraj

Effect of Androgen Deprivation Therapy on Sexual Function

Androgen Deprivation Therapy and Prostate Cancer

The Controversy About Androgen Deprivation Therapy and …/media/Non-Clinical/Files-PDFs-Excel... · 2019. 1. 30. · The Controversy About Androgen Deprivation Therapy and Cardiovascular